SciSparc
Giv'atayim · Founded 2014
About SciSparc
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol (CBD): THX-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; THX-160 for the treatment of pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy.
Company Facts
- Founded: 2014
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $24.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Oct 2023)
- Ticker: nasdaq:SPRC
- Website: investor.scisparc.com
- Phone: 97236167055
Industries & Categories
Biotechnology, Cannabis, Medical
Social Profiles
Canonical: https://fsome.com/organization/scisparc-23337 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.